Adamantinomatous craniopharyngioma: advances in proteomic research
- PMID: 32617710
- DOI: 10.1007/s00381-020-04750-z
Adamantinomatous craniopharyngioma: advances in proteomic research
Abstract
Background: Many efforts have been performed in the last decade to accomplish the genomic and proteomic characterization of pediatric adamantinomatous craniopharyngioma with the purpose to elucidate the molecular mechanisms underlying the onset and development of this pediatric brain tumor, its high recurrence rate, and, although classified as a histologically benign neoplasm, its aggressive behavior.
Methods: The focus of this review is to perform the new comparison of the proteomic profiles of the solid component and the intracystic fluid of adamantinomatous craniopharyngioma based on our previous results, obtained by both the top-down and the bottom-up proteomic approaches, to disclose differences and similarities, and to discuss the results in the context of the most recent literature.
Results and conclusions: Proteins and peptides identified in the cyst fluid and in the solid component of adamantinomatous craniopharyngioma (AC) include beyond markers of inflammation (i.e., alpha-defensins), proteins involved in cell migration and protein degradation (i.e., beta-thymosin and ubiquitin peptides), whose main role might be in tumor growth and infiltration of the surrounding neural structures. These last appeared different in the solid components compared with the cyst fluid, missing their terminal part in the solid tissue, a feature generally associated to malignancies, which might represent a distinct molecular site for an aggressive behavior of AC.
Keywords: Adamantinomatous craniopharyngioma; Pediatric brain tumor; Proteomics.
References
-
- Massimi L, Martelli C, Caldarelli M, Castagnola M, Desiderio C (2017) Proteomics in pediatric cystic craniopharyngioma. Brain Pathol 27:370–376 - PubMed
-
- Hengartner AC, Prince E, Vijmasi T Hankinson TC (2020) Adamantinomatous craniopharyngioma: moving toward targeted therapies. Neurosurg Focus 48:E7
-
- Whelan R, Prince E, Gilani A, Hankinson T (2020) The inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment. J Clin Med 9:519 - PMC
-
- Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, Niazi TN, Grant G, Souweidane M, Johnston JM, Jackson EM, Kleinschmidt-DeMasters B, Handler MH, Tan AC, Gore L, Virasami A, Gonzalez-Meljem JM, Jacques TS, Martinez-Barbera JP, Foreman NK, Hankinson TC, Advancing Treatment for Pediatric Craniopharyngioma Consortium (2017) Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma. J Neuropathol Exp Neurol 76:779–788 - PubMed - PMC
-
- Iavarone F, Desiderio C, Vitali A, Messana I, Martelli C, Castagnola M, Cabras T (2018) Cryptides: latent peptides everywhere. Crit Rev Biochem Mol Biol 53:246–263 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
